ONCS News .20 ONCOSEC MEDICAL
Symbol U : ONCS
Recent Sedar Documents 
OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012

2012-06-26 06:09 ET - News Release

Enrollment for Phase II Study is Now 50 Percent Complete

SAN DIEGO, June 26, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB:ONCS), a company developing the OncoSec Medical System (OMS) ElectroOncology therapies to treat advanced-stage solid tumors, announced that Dr. Adil Daud, principal investigator, presented preliminary enrollment and safety data at the Second European Post-Chicago Melanoma Meeting in Munich, Germany for the company's on-going Phase II metastatic melanoma clinical trial, OMS-I100.